Søren Tang Knudsen
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Søren Tang Knudsen has a total of 77 co-authors. Here are the top co-authors by number of shared publications:
- Esben Laugesen
Steno Diabetes Center Aarhus, Aarhus University Hospital, Aarhus, Denmark
4 shared publications - Frederik Persson
Steno Diabetes Center Copenhagen, Herlev, Denmark
2 shared publications - Per Løgstrup Poulsen
Department of Clinical Medicine, Aarhus University, 8000 Aarhus, Denmark; Steno Diabetes Center, Aarhus University Hospital, 8200 Aarhus N, Denmark
2 shared publications A.‐M. Catarig
Novo Nordisk A/S, Copenhagen, Denmark
1 shared publication- Anders Abildgaard
Department of Clinical Biochemistry, Aarhus University Hospital , Aarhus
1 shared publication Anders Lindh
Åkersberga, Sweden
1 shared publication
Latest Publications
- Open Access
- 7 August 2026
- Published by Elsevier in Endocrine Practice
Metformin and Vitamin B12 Deficiency: A Prevalence Study
- 7 August 2026
- Published by Elsevier in Endocrine Practice
Open AccessMetformin and Vitamin B12 Deficiency: A Prevalence Study
- Open Access
- 6 May 2025
- Published by Elsevier in Primary Care Diabetes
- Vol. 19 (4) , 368-374
Evaluating risk stratification according to Type 2 diabetes guidelines in primary care – Insights from the Danish DIAGRAM project
- 6 May 2025
- Published by Elsevier in Primary Care Diabetes
- Vol. 19 (4) , 368-374
Open AccessEvaluating risk stratification according to Type 2 diabetes guidelines in primary care – Insights from the Danish DIAGRAM project
- Open Access
- 1 December 2021
- Published by Elsevier in Primary Care Diabetes
- Vol. 15 (6) , 1007-1011
Improving frequency of urinary albumin testing in type 2 diabetes in primary care — An analysis of cross-sectional studies in Denmark
- 1 December 2021
- Published by Elsevier in Primary Care Diabetes
- Vol. 15 (6) , 1007-1011
Open AccessImproving frequency of urinary albumin testing in type 2 diabetes in primary care — An analysis of cross-sectional studies in Denmark
- Open Access
- 1 October 2021
- Published by Elsevier in Primary Care Diabetes
- Vol. 15 (5) , 871-878
Real-world use of once-weekly semaglutide in patients with type 2 diabetes: Results from the SURE Denmark/Sweden multicentre, prospective, observational study
- 1 October 2021
- Published by Elsevier in Primary Care Diabetes
- Vol. 15 (5) , 871-878
Open AccessReal-world use of once-weekly semaglutide in patients with type 2 diabetes: Results from the SURE Denmark/Sweden multicentre, prospective, observational study
- Open Access
- 1 April 2021
- Published by Elsevier in Primary Care Diabetes
- Vol. 15 (2) , 262-268
Risk factor management of type 2 diabetic patients in primary care in the Scandinavian countries between 2003 and 2015
- 1 April 2021
- Published by Elsevier in Primary Care Diabetes
- Vol. 15 (2) , 262-268
Open AccessRisk factor management of type 2 diabetic patients in primary care in the Scandinavian countries between 2003 and 2015
- Open Access
- 30 September 2020
- Published by American Diabetes Association in Diabetes Care
- Vol. 43 (12) , 2945-2952
Statin Therapy and Risk of Polyneuropathy in Type 2 Diabetes: A Danish Cohort Study
OBJECTIVE: Statins may reduce the risk of diabetic polyneuropathy (DPN) as a result of lipid-lowering and anti-inflammatory effects, but statins have also been associated with neurotoxicity. We examined whether statin therapy affects the risk of DPN.RESEARCH DESIGN AND METHODS: We identified all Danish patients with incident type 2 diabetes during 2002–2016. New users initiated statins between 180 days before and 180 days after their first diabetes record, while prevalent users had initiated statins before that period. Patients were followed for incident DPN using validated hospital diagnosis codes, starting 180 days after their first diabetes record. Cox proportional hazard analysis was used to compute adjusted hazard ratios (aHRs) for DPN.RESULTS: The study cohort comprised 59,255 (23%) new users, 75,528 (29%) prevalent users, and 124,842 (48%) nonusers; median follow-up time was 6.2 years (interquartile range 3.4–9.6). The incidence rate of DPN events per 1,000 person-years was similar in new users (4.0 [95% CI 3.8–4.2]), prevalent users (3.8 [3.6–3.9]), and nonusers (3.8 [3.7–4.0]). The aHR for DPN was 1.05 (0.98–1.11) in new users and 0.97 (0.91–1.04) in prevalent users compared with statin nonusers. New users had a slightly increased DPN risk during the first year (1.31 [1.12–1.53]), which vanished after >2 years of follow-up. Findings were similar in on-treatment and propensity score–matched analyses and with additional adjustment for pretreatment blood lipid levels.CONCLUSIONS: Statin therapy is unlikely to increase or mitigate DPN risk in patients with type 2 diabetes, although a small acute risk of harm cannot be excluded.
- 30 September 2020
- Published by American Diabetes Association in Diabetes Care
- Vol. 43 (12) , 2945-2952
Open AccessStatin Therapy and Risk of Polyneuropathy in Type 2 Diabetes: A Danish Cohort Study
OBJECTIVE: Statins may reduce the risk of diabetic polyneuropathy (DPN) as a result of lipid-lowering and anti-inflammatory effects, but statins have also been associated with neurotoxicity. We examined whether statin therapy affects the risk of DPN.RESEARCH DESIGN AND METHODS: We identified all Danish patients with incident type 2 diabetes during 2002–2016. New users initiated statins between 180 days before and 180 days after their first diabetes record, while prevalent users had initiated statins before that period. Patients were followed for incident DPN using validated hospital diagnosis codes, starting 180 days after their first diabetes record. Cox proportional hazard analysis was used to compute adjusted hazard ratios (aHRs) for DPN.RESULTS: The study cohort comprised 59,255 (23%) new users, 75,528 (29%) prevalent users, and 124,842 (48%) nonusers; median follow-up time was 6.2 years (interquartile range 3.4–9.6). The incidence rate of DPN events per 1,000 person-years was similar in new users (4.0 [95% CI 3.8–4.2]), prevalent users (3.8 [3.6–3.9]), and nonusers (3.8 [3.7–4.0]). The aHR for DPN was 1.05 (0.98–1.11) in new users and 0.97 (0.91–1.04) in prevalent users compared with statin nonusers. New users had a slightly increased DPN risk during the first year (1.31 [1.12–1.53]), which vanished after >2 years of follow-up. Findings were similar in on-treatment and propensity score–matched analyses and with additional adjustment for pretreatment blood lipid levels.CONCLUSIONS: Statin therapy is unlikely to increase or mitigate DPN risk in patients with type 2 diabetes, although a small acute risk of harm cannot be excluded.
- 14 November 2019
- Published by Wiley in Diabetes, Obesity and Metabolism
- Vol. 22 (S2) , 12-18
Renal protection: What have we learnt from ADVANCE about kidney disease in type 2 diabetes?
The Action in Diabetes and Vascular Disease: Preterax and Diamicron Modified Release Controlled Evaluation (ADVANCE) factorial trial was a landmark randomized controlled clinical trial in 11 140 type 2 diabetic patients from 215 centers in 20 countries with a two‐by‐two factorial design. In the blood pressure‐lowering arm, patients were treated using a fixed combination of the ACE‐inhibitor, perindopril, and the thiazide‐like diuretic, indapamide, or placebo, whereas in the glucose‐lowering arm, the intervention compared the sulphonylurea gliclazide plus other glucose‐lowering drugs, targeting a glycated hemoglobin value of 6.5% or less, with standard glucose control. Primary end‐points were major macro‐ and microvascular events in both arms. This review gives an overview of the results of the primary randomized trial, results from observational follow‐up studies, and results of several biomarker studies and discusses the perspectives of these data in the context of recent major outcome trials for current medical treatment.
- 14 November 2019
- Published by Wiley in Diabetes, Obesity and Metabolism
- Vol. 22 (S2) , 12-18
Renal protection: What have we learnt from ADVANCE about kidney disease in type 2 diabetes?
The Action in Diabetes and Vascular Disease: Preterax and Diamicron Modified Release Controlled Evaluation (ADVANCE) factorial trial was a landmark randomized controlled clinical trial in 11 140 type 2 diabetic patients from 215 centers in 20 countries with a two‐by‐two factorial design. In the blood pressure‐lowering arm, patients were treated using a fixed combination of the ACE‐inhibitor, perindopril, and the thiazide‐like diuretic, indapamide, or placebo, whereas in the glucose‐lowering arm, the intervention compared the sulphonylurea gliclazide plus other glucose‐lowering drugs, targeting a glycated hemoglobin value of 6.5% or less, with standard glucose control. Primary end‐points were major macro‐ and microvascular events in both arms. This review gives an overview of the results of the primary randomized trial, results from observational follow‐up studies, and results of several biomarker studies and discusses the perspectives of these data in the context of recent major outcome trials for current medical treatment.
- Open Access
- 18 April 2019
- Published by Wiley in Diabetic Medicine
- Vol. 36 (7) , 868-877
Clinical benefits of switching to insulin degludec irrespective of previous basal insulin therapy in people with Type 1 or Type 2 diabetes: evidence from a European, multicentre, retrospective, non‐interventional study (EU‐TREAT)
Aims To investigate whether the benefits of switching to insulin degludec observed in the European retrospective chart review study EU‐TREAT were dependent on the previous basal insulin used. Methods People with Type 1 or Type 2 diabetes were switched to insulin degludec from other basal insulins ≥6 months before data collection. Participants were stratified into three groups based on their previous basal insulin: insulin glargine 100 units/ml (Type 1: n=888; Type 2: n=259); insulin detemir (Type 1: n=726; Type 2: n=415); and neutral protamine Hagedorn (Type 1: n=53; Type 2: n=95). Their glycaemic control and hypoglycaemia incidence at 6 and 12 months post‐switch vs pre‐switch was then evaluated. Results Significant HbA1c reductions were achieved in all previous basal insulin groups for participants with Type 1 diabetes [insulin glargine 100 units/ml: −2.08 mmol/mol (−0.19%); insulin detemir: −2.40 mmol/mol (−0.22%)] and those with Type 2 diabetes [insulin glargine 100 units/ml: −5.90 mmol/mol (–0.54%); insulin detemir: −6.01 mmol/mol (−0.55%); neutral protamine Hagedorn: −2.73 mmol/mol (−0.25%)] at 6 months, except for the relatively small neutral protamine Hagedorn group in those with Type 1 diabetes [−1.75 mmol/mol (−0.16%)], where statistical significance was not reached. At 6 months in the Type 1 diabetes group, switching to insulin degludec from insulin glargine 100 units/ml resulted in significantly lower hypoglycaemia rates across all hypoglycaemia categories; for the insulin detemir group, this significance was also observed for severe and nocturnal non‐severe hypoglycaemia, while the low number of people in the neutral protamine Hagedorn group resulted in nonsignificant reductions in hypoglycaemia rates. At 6 months in the people with Type 2 diabetes, switching to insulin degludec resulted in significantly lower rates of hypoglycaemia across all categories for all groups. Similar outcomes were observed at 12 months. Conclusions Switching to insulin degludec from other basal insulins can improve glycaemic control and/or reduce hypoglycaemia risk in people with diabetes (although there was a nonsignificant reduction in HbA1c and hypoglycaemia rates for the neutral protamine Hagedorn group in Type 1 diabetes) under routine care.
- 18 April 2019
- Published by Wiley in Diabetic Medicine
- Vol. 36 (7) , 868-877
Open AccessClinical benefits of switching to insulin degludec irrespective of previous basal insulin therapy in people with Type 1 or Type 2 diabetes: evidence from a European, multicentre, retrospective, non‐interventional study (EU‐TREAT)
Aims To investigate whether the benefits of switching to insulin degludec observed in the European retrospective chart review study EU‐TREAT were dependent on the previous basal insulin used. Methods People with Type 1 or Type 2 diabetes were switched to insulin degludec from other basal insulins ≥6 months before data collection. Participants were stratified into three groups based on their previous basal insulin: insulin glargine 100 units/ml (Type 1: n=888; Type 2: n=259); insulin detemir (Type 1: n=726; Type 2: n=415); and neutral protamine Hagedorn (Type 1: n=53; Type 2: n=95). Their glycaemic control and hypoglycaemia incidence at 6 and 12 months post‐switch vs pre‐switch was then evaluated. Results Significant HbA1c reductions were achieved in all previous basal insulin groups for participants with Type 1 diabetes [insulin glargine 100 units/ml: −2.08 mmol/mol (−0.19%); insulin detemir: −2.40 mmol/mol (−0.22%)] and those with Type 2 diabetes [insulin glargine 100 units/ml: −5.90 mmol/mol (–0.54%); insulin detemir: −6.01 mmol/mol (−0.55%); neutral protamine Hagedorn: −2.73 mmol/mol (−0.25%)] at 6 months, except for the relatively small neutral protamine Hagedorn group in those with Type 1 diabetes [−1.75 mmol/mol (−0.16%)], where statistical significance was not reached. At 6 months in the Type 1 diabetes group, switching to insulin degludec from insulin glargine 100 units/ml resulted in significantly lower hypoglycaemia rates across all hypoglycaemia categories; for the insulin detemir group, this significance was also observed for severe and nocturnal non‐severe hypoglycaemia, while the low number of people in the neutral protamine Hagedorn group resulted in nonsignificant reductions in hypoglycaemia rates. At 6 months in the people with Type 2 diabetes, switching to insulin degludec resulted in significantly lower rates of hypoglycaemia across all categories for all groups. Similar outcomes were observed at 12 months. Conclusions Switching to insulin degludec from other basal insulins can improve glycaemic control and/or reduce hypoglycaemia risk in people with diabetes (although there was a nonsignificant reduction in HbA1c and hypoglycaemia rates for the neutral protamine Hagedorn group in Type 1 diabetes) under routine care.
- Open Access
- 12 July 2016
- Published by Oxford University Press (OUP) in American Journal of Hypertension
- Vol. 29 (10) , 1165-1172
Reduced Subendocardial Viability Ratio Is Associated With Unfavorable Cardiovascular Risk Profile in Women With Short Duration of Type 2 Diabetes
The pathophysiological perturbations underlying the unfavorable cardiovascular prognosis in women with type 2 diabetes (T2DM) remain elusive. Low subendocardial viability ratio (SEVR), an index of myocardial oxygen supply and demand, has been associated with intermediate cardiovascular risk markers and cardiovascular mortality in various populations. However, whether SEVR is associated with sex and cardiovascular risk markers in patients with T2DM remains to be clarified. We examined 86 T2DM patients (mean age 59±10 years, 47% women, median diabetes duration 1.9 (range 0.2–5.0) years) and 86 sex- and age-matched control subjects in a cross-sectional study. SEVR was noninvasively assessed by tonometry and markers of cardiovascular risk by carotid-femoral pulse wave velocity (PWV), homeostasis model assessment of insulin resistance (HOMA2-IR), C-reactive protein, urinary albumin/creatinine ratio, and heart rate variability. Women with diabetes had significantly lower SEVR compared to both men with diabetes (161% ± 26% vs. 178% ± 32%, P < 0.01), women without diabetes (185% ± 24%, P < 0.001), and men without diabetes (188% ± 28%, P < 0.001). The differences remained significant after adjustment for age, systolic blood pressure, heart rate, diabetes, and smoking. SEVR was associated with PWV, HOMA2-IR, C-reactive protein, and reduced heart rate variability in patients and control subjects, but the associations became nonsignificant after adjustment for heart rate. SEVR is reduced in women with short duration of T2DM and associated with cardiovascular risk markers. The latter association seems to be at least partly mediated via heart rate. We hypothesize that reduced SEVR may contribute to the unfavorable cardiovascular prognosis in women with diabetes.
- 12 July 2016
- Published by Oxford University Press (OUP) in American Journal of Hypertension
- Vol. 29 (10) , 1165-1172
Open AccessReduced Subendocardial Viability Ratio Is Associated With Unfavorable Cardiovascular Risk Profile in Women With Short Duration of Type 2 Diabetes
The pathophysiological perturbations underlying the unfavorable cardiovascular prognosis in women with type 2 diabetes (T2DM) remain elusive. Low subendocardial viability ratio (SEVR), an index of myocardial oxygen supply and demand, has been associated with intermediate cardiovascular risk markers and cardiovascular mortality in various populations. However, whether SEVR is associated with sex and cardiovascular risk markers in patients with T2DM remains to be clarified. We examined 86 T2DM patients (mean age 59±10 years, 47% women, median diabetes duration 1.9 (range 0.2–5.0) years) and 86 sex- and age-matched control subjects in a cross-sectional study. SEVR was noninvasively assessed by tonometry and markers of cardiovascular risk by carotid-femoral pulse wave velocity (PWV), homeostasis model assessment of insulin resistance (HOMA2-IR), C-reactive protein, urinary albumin/creatinine ratio, and heart rate variability. Women with diabetes had significantly lower SEVR compared to both men with diabetes (161% ± 26% vs. 178% ± 32%, P < 0.01), women without diabetes (185% ± 24%, P < 0.001), and men without diabetes (188% ± 28%, P < 0.001). The differences remained significant after adjustment for age, systolic blood pressure, heart rate, diabetes, and smoking. SEVR was associated with PWV, HOMA2-IR, C-reactive protein, and reduced heart rate variability in patients and control subjects, but the associations became nonsignificant after adjustment for heart rate. SEVR is reduced in women with short duration of T2DM and associated with cardiovascular risk markers. The latter association seems to be at least partly mediated via heart rate. We hypothesize that reduced SEVR may contribute to the unfavorable cardiovascular prognosis in women with diabetes.